Targeting host factors to treat West Nile and dengue viral infections

Manoj N. Krishnan, Mariano Garcia-Blanco

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

West Nile (WNV) and Dengue (DENV) viruses are major arboviral human pathogens belonging to the genus Flavivirus. At the current time, there are no approved prophylactics (e.g., vaccines) or specific therapeutics available to prevent or treat human infections by these pathogens. Due to their minimal genome, these viruses require many host molecules for their replication and this offers a therapeutic avenue wherein host factors can be exploited as treatment targets. Since several host factors appear to be shared by many flaviviruses the strategy may result in pan-flaviviral inhibitors and may also attenuate the rapid emergence of drug resistant mutant viruses. The scope of this strategy is greatly enhanced by the recent en masse identification of host factors impacting on WNV and DENV infection. Excellent proof-of-principle experimental demonstrations for host-targeted control of infection and infection-induced pathogenesis have been reported for both WNV and DENV. These include exploiting not only those host factors supporting infection, but also targeting host processes contributing to pathogenesis and innate immune responses. While these early studies validated the host-targeting approach, extensive future investigations spanning a range of aspects are needed for a successful deployment in humans.

Original languageEnglish (US)
Pages (from-to)683-708
Number of pages26
JournalViruses
Volume6
Issue number2
DOIs
StatePublished - Feb 10 2014
Externally publishedYes

Fingerprint

Dengue
Virus Diseases
Flavivirus
Infection
Viruses
Dengue Virus
Infection Control
Innate Immunity
Vaccines
Genome
Therapeutics
Pharmaceutical Preparations

Keywords

  • Dengue virus
  • Drug targets
  • Host factor
  • West Nile virus

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Cite this

Targeting host factors to treat West Nile and dengue viral infections. / Krishnan, Manoj N.; Garcia-Blanco, Mariano.

In: Viruses, Vol. 6, No. 2, 10.02.2014, p. 683-708.

Research output: Contribution to journalArticle

@article{7a3c90f588ff49fc94a09f9b5c11e2e2,
title = "Targeting host factors to treat West Nile and dengue viral infections",
abstract = "West Nile (WNV) and Dengue (DENV) viruses are major arboviral human pathogens belonging to the genus Flavivirus. At the current time, there are no approved prophylactics (e.g., vaccines) or specific therapeutics available to prevent or treat human infections by these pathogens. Due to their minimal genome, these viruses require many host molecules for their replication and this offers a therapeutic avenue wherein host factors can be exploited as treatment targets. Since several host factors appear to be shared by many flaviviruses the strategy may result in pan-flaviviral inhibitors and may also attenuate the rapid emergence of drug resistant mutant viruses. The scope of this strategy is greatly enhanced by the recent en masse identification of host factors impacting on WNV and DENV infection. Excellent proof-of-principle experimental demonstrations for host-targeted control of infection and infection-induced pathogenesis have been reported for both WNV and DENV. These include exploiting not only those host factors supporting infection, but also targeting host processes contributing to pathogenesis and innate immune responses. While these early studies validated the host-targeting approach, extensive future investigations spanning a range of aspects are needed for a successful deployment in humans.",
keywords = "Dengue virus, Drug targets, Host factor, West Nile virus",
author = "Krishnan, {Manoj N.} and Mariano Garcia-Blanco",
year = "2014",
month = "2",
day = "10",
doi = "10.3390/v6020683",
language = "English (US)",
volume = "6",
pages = "683--708",
journal = "Viruses",
issn = "1999-4915",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "2",

}

TY - JOUR

T1 - Targeting host factors to treat West Nile and dengue viral infections

AU - Krishnan, Manoj N.

AU - Garcia-Blanco, Mariano

PY - 2014/2/10

Y1 - 2014/2/10

N2 - West Nile (WNV) and Dengue (DENV) viruses are major arboviral human pathogens belonging to the genus Flavivirus. At the current time, there are no approved prophylactics (e.g., vaccines) or specific therapeutics available to prevent or treat human infections by these pathogens. Due to their minimal genome, these viruses require many host molecules for their replication and this offers a therapeutic avenue wherein host factors can be exploited as treatment targets. Since several host factors appear to be shared by many flaviviruses the strategy may result in pan-flaviviral inhibitors and may also attenuate the rapid emergence of drug resistant mutant viruses. The scope of this strategy is greatly enhanced by the recent en masse identification of host factors impacting on WNV and DENV infection. Excellent proof-of-principle experimental demonstrations for host-targeted control of infection and infection-induced pathogenesis have been reported for both WNV and DENV. These include exploiting not only those host factors supporting infection, but also targeting host processes contributing to pathogenesis and innate immune responses. While these early studies validated the host-targeting approach, extensive future investigations spanning a range of aspects are needed for a successful deployment in humans.

AB - West Nile (WNV) and Dengue (DENV) viruses are major arboviral human pathogens belonging to the genus Flavivirus. At the current time, there are no approved prophylactics (e.g., vaccines) or specific therapeutics available to prevent or treat human infections by these pathogens. Due to their minimal genome, these viruses require many host molecules for their replication and this offers a therapeutic avenue wherein host factors can be exploited as treatment targets. Since several host factors appear to be shared by many flaviviruses the strategy may result in pan-flaviviral inhibitors and may also attenuate the rapid emergence of drug resistant mutant viruses. The scope of this strategy is greatly enhanced by the recent en masse identification of host factors impacting on WNV and DENV infection. Excellent proof-of-principle experimental demonstrations for host-targeted control of infection and infection-induced pathogenesis have been reported for both WNV and DENV. These include exploiting not only those host factors supporting infection, but also targeting host processes contributing to pathogenesis and innate immune responses. While these early studies validated the host-targeting approach, extensive future investigations spanning a range of aspects are needed for a successful deployment in humans.

KW - Dengue virus

KW - Drug targets

KW - Host factor

KW - West Nile virus

UR - http://www.scopus.com/inward/record.url?scp=84893952668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893952668&partnerID=8YFLogxK

U2 - 10.3390/v6020683

DO - 10.3390/v6020683

M3 - Article

VL - 6

SP - 683

EP - 708

JO - Viruses

JF - Viruses

SN - 1999-4915

IS - 2

ER -